Arcturus Therapeutics (ARCT) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Immuneering (IMRX) over the past year, gaining 19.0% versus a loss of 53.7%. Over five years, ARCT leads with a -81.3% price change compared with -85.0% for IMRX. Immuneering is the larger company by market cap ($218.9 million vs $214.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | IMRX |
|---|---|---|
| Share price | $7.45 | $3.38 |
| Market cap | $214.73M | $218.90M |
| 1-day change | -1.97% | -2.03% |
| YTD return | +21.53% | -48.63% |
| 1-year return | +19.01% | -53.70% |
| 5-year return | -81.32% | -85.00% |
| EPS (TTM) | $-3.10 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | — |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $-56.02M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $17.96 | $8.48 |
| 52-week low | $5.50 | $3.29 |
| Distance from 52-week high | -58.52% | -60.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.12% | +402.96% |
| Average volume | 851.45K | 747.66K |
| Shares outstanding | 28.82M | 64.76M |
| Employees | 106 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed IMRX by 72.7 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ARCT vs IMRX FAQ
Which is bigger, Arcturus Therapeutics or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $214.73M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or IMRX?
ARCT returned +19.01% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.